Goldman Sachs’ Four Zones Within Capital Market Coverage, Gives Stock Picks
Goldman Sachs Group Inc (NYSE: GS) has outlined four themes for 2023 amid recessionary risks and rising interest rates.
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023.
Justice Department Convicts New York Person For Stealing General Electric Trade Secrets For China
The U.S. Justice Department said that a New York man was convicted for conspiring to steal General Electric Company's (NYSE: GE) trade secrets to benefit China.
FDA Permits Retail Pharmacies To Distribute Abortion Pills, Expanding Access After Supreme Court Ruling
The FDA will allow pharmacies to offer abortion pills, mifepristone, in the U.S. Pharmacies must complete a form for certification…
Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings
As Sanofi SA (NASDAQ:SNY) schedules to report Q4 FY22 earnings early next month, it expects a positive currency impact in Q4 2022.…
Goldman Sachs Bullish On M&A Deals Activity Picking Up In Late 2023
Goldman Sachs Group Inc (NYSE: GS) seems to be bullish on the recovery of global mergers & acquisition deals in the second half of 2023 despite slow economic growth and a weak credit market.
Why This Bank Analyst Is No Longer Bullish On Ally, Capital One
Banks are entering 2023 in a state of alert as national and global economies slide into a period of ever-increasing uncertainty.
Southwest Airlines More Or Less Returns To Normal Schedule Amid Processing Refunds
Southwest Airlines Co (NYSE: LUV) restored to more-normal operations this weekend after a cascade of flight cancellations over the holidays.
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study
Valneva SE (NASDAQ:VALN) reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001. The…
Is Tesla’s Q4 Delivery Miss Cause For Concern? ‘Bulls Will Not Be Super Happy’
Tesla (NASDAQ: TSLA) reported its year-end vehicle production and delivery numbers for 2022 on Monday, falling behind Wall Street estimates by about 3%.